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Mycophenolate mofetil attenuates renal injury in the rat remnant
kidney.
Background. Mycophenolate mofetil (MMF), an inhibitor of
lymphocyte proliferation, has been used to prevent allograft
rejection. We investigated whether MMF also limits progressive
renal injury in rats with 5/6 renal ablation, a model not primarily
related to immunologic mechanisms.
Methods. Eighty-eight adult male Munich-Wistar rats under-
went ablation and received either vehicle (N 5 42) or oral MMF
(N 5 46), 10 mg/kg/day. Forty-seven sham-operated rats were also
studied.
Results. Thirty days after surgery, remnant kidneys exhibited
glomerular hypertension and hypertrophy. MMF treatment did
not correct these abnormalities. Immunohistochemistry revealed
interstitial lymphocyte infiltration 7 and 30 days after ablation.
Proliferating cells abounded seven days after ablation, especially
in tubules, declining in number along the following weeks. By
contrast, the number of macrophages was moderately increased in
the first weeks, attaining values eightfold as high as control 60
days after ablation. MMF attenuated these cellular events at all
phases of the study. Sixty days after ablation, marked albuminuria,
glomerulosclerosis and interstitial expansion were prominent in
untreated rats. MMF treatment largely attenuated glomerular and
interstitial injury without changing proteinuria.
Conclusion. This is the first evidence that MMF may impact
favorably on progressive renal diseases of “nonimmunologic”
origin.
The exact pathogenic mechanisms underlying the pro-
gression of chronic renal disease are largely unknown.
Although mechanical factors such as glomerular hyperten-
sion and hypertrophy likely contribute to initiate at least
some forms of progressive renal disease [1–3], there is
growing evidence that cellular events such as cell prolifer-
ation [4, 5], macrophage activation [6] and local production
of inflammatory mediators [7, 8] are key to the propagation
of injury in these processes. Special attention has been
focused on the role of both native cells and infiltrating
inflammatory cells, such as macrophages, lymphocytes and
fibroblasts, in the production of a large spectrum of cyto-
kines, growth factors, vasoactive compounds and other
inflammatory mediators [7, 8].
Recently, mycophenolate mofetil (MMF), previously
shown to prolong allograft survival in animals [9], has been
introduced in clinical transplantation protocols as an effec-
tive and potent immunosuppressive drug [10, 11]. After
oral administration, MMF is converted into its active
metabolite, mycophenolic acid (MPA). MPA is a potent
inhibitor of inosine monophosphate dehydrogenase [12,
13], a key enzyme in the de novo synthesis of guanosine
59-triphosphate (GTP). In most eukaryotic cells, this effect
has little impact on proliferation due to the existence of a
salvage pathway. Since lymphocytes rely heavily on the de
novo route, MPA depletes their intracellular GTP pool and
specifically inhibits their proliferation, thus limiting cell-
mediated immune mechanisms [12, 13]. Additional antiin-
flammatory actions may derive from inhibition of adhesion
molecules, which may limit the migration of lymphocytes
and other inflammatory cells [14].
In the present study, we examined the hypothesis that
MPA, by inhibiting local inflammatory phenomena, retards
the progression of chronic renal disease. To accomplish this
goal, we administered MMF to rats with 5/6 renal ablation
(NX), a model of progressive renal disease thought to be
initiated by nonimmunologic mechanisms. In this manner,
we were able to directly evaluate the role of cell-mediated
immunity in the development of renal injury in this model.
METHODS
One-hundred thirty-five adult male Munich-Wistar rats
obtained from our own breeding colony, with initial weights
of 240 to 270 g, were used in this study. All rats received
food (22% protein) and tap water ad libitum. Surgical
reduction of renal mass (NX) was performed under anes-
thesia with sodium pentobarbital, 50 mg/kg i.p., by removal
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of the right kidney and infarction of approximately two-
thirds of the left one. Sham-operated rats (Sham) under-
went anesthesia, ventral laparotomy and manipulation of
the renal pedicles, without removal of renal mass. MMF
(Roche Laboratories, Nutley, NJ, USA) was dissolved in a
mixture of dimethylsulfoxide and olive oil, the final con-
centration of dimethylsulfoxide being 5%. The compound
was given by gavage daily in a volume of vehicle never
exceeding 0.3 ml. Untreated rats received vehicle only. All
experimental procedures were conducted in accordance
with our institutional guidelines.
Experimental groups
Three experimental groups were studied: (1) Sham (N 5
47), sham-operated rats; (2) NX (N 5 42), rats subjected to
5/6 renal removal and treated with vehicle only; and (3)
NX1MMF (N 5 46), rats receiving MMF, 10 mg/kg/day.
This dosage, which is somewhat lower than that usually
employed to prevent murine graft rejection [10, 14], was
found to be the highest dose that still promoted no body
growth stunting, anemia or deterioration of the rats’ gen-
eral condition.
The Sham Group included both untreated and MMF-
treated sham-operated rats, since long-term MMF treat-
ment promoted no renal functional or structural alterations
(see Results).
Renal hemodynamic studies
To examine renal functional parameters, eight rats of
each group were subjected to micropuncture experiments
30 days after renal ablation. Rats were anesthetized with
Inactin (100 mg/kg of body wt, i.p.) and placed on a
temperature-regulated table. The femoral artery was cath-
eterized with PE-50 tubing to determine baseline hemato-
crit and subsequent periodic blood sampling, as well as for
continuous monitoring of mean arterial pressure with a
P23Db Statham pressure transducer connected to a chart
recorder (Model TA 240; Gould Inc., OH, USA). Euvol-
emia was maintained by intravenous infusion of homolo-
gous rat plasma. Saline solution containing 14C-tagged
inulin (0.3 mCi/ml) was infused at 1.5 ml/hr. After about 2.5
hours of anesthesia, urine was collected from the left ureter
for 20 to 30 minutes for the determination of flow rate and
inulin concentration. Hydraulic pressures in superficial
glomeruli (PGC), tubules, and arterioles were determined
with a servo-nulling device (Model V; Instrumentation for
Physiology and Medicine, San Diego, CA, USA). Whole-
kidney filtration fraction (FF) was determined by the
simultaneous collection of blood samples from the femoral
artery and renal vein and the assessment of the respective
14C activities to calculate inulin extraction. Blood samples
were obtained from the renal vein with a sharpened glass
micropipette, 40 to 45 mm OD. Plasma and urine 14C
activities were measured in a scintillation counter (Beck-
man Instruments, Shiller Park, IL, USA). Renal plasma
flow (RPF) was calculated as RPF 5 GFR/FF, where GFR
represents glomerular filtration rate. Renal vascular resis-
tance (RVR) was estimated by the expression RVR 5
MAP z (1 2 Hct)/RPF, where MAP and Hct represents
mean arterial pressure and arterial hematocrit, respec-
tively. At the end of each experiment, the renal tissue was
perfusion-fixed for later histologic analysis (see below).
Sixty-day follow-up studies
Ten Sham rats, 10 rats from Group NX and 15 rats from
Group NX1MMF were monitored along 60 days of treat-
ment. Urinary albumin excretion rate was measured at 30
and 60 days after ablation. At the end of the study period,
awake systemic arterial pressure was evaluated by a tail-
cuff method [15]. Plasma creatinine concentration (PCr)
was also determined at this time. Rats were then anesthe-
tized with sodium pentobarbital, 50 mg/kg i.p. for perfu-
sion-fixation of the renal tissue (see below).
Preparation of renal tissue for morphologic analysis
The remnant kidneys of rats utilized for the functional
and follow-up studies were perfusion-fixed by in situ perfu-
sion at the measured arterial pressure with Duboscq-Brazil
solution after a brief saline flush. After fixation, the renal
tissue was weighed, and two midcoronal sections through
the mid portion of the remnant kidney were postfixed in
buffered 4% formaldehyde solution and embedded in
paraffin for simple histologic examination as well as for
immunohistochemical identification of macrophages and
proliferating activity (see below). Renal tissue was obtained
from additional rats of each group seven (N 5 6) and
fourteen (N 5 6) days after ablation, and processed in the
same manner for immunohistochemical analysis.
The expression of T-lymphocytes was analyzed in six
additional rats of each group seven and thirty days after
ablation. For this purpose, rats were anesthetized with
pentobarbital and the renal tissue was snap-frozen in liquid
nitrogen and stored at 270°C until processing.
Histomorphometry
Sections 2 to 3 mm thick were stained with periodic
acid-Schiff reaction and by the Masson trichrome tech-
nique. The average glomerular tuft volume (VG) at 30 days
of ablation was estimated by the method of Weibel [16],
after light microscopic examination at a final magnification
of 3 320 under a 100-point ocular grid. The corresponding
microscopic field covered an area of 133.932 mm2. The
mean glomerular cross-sectional area (AG) was determined
for each rat by averaging individual values for at least 50
randomly sampled glomerular tuft profiles. Individual glo-
merular values were calculated by counting points falling
within the glomerular area. VG was then calculated as: VG
5 1.25 z (AG)
3/2 [17].
The extent of glomerulosclerosis was evaluated by attrib-
uting a score to each glomerulus according to the extent of
Fujihara et al: Mycophenolate in renal ablation 1511
sclerotic injury: zero 5 intact glomeruli; 1 5 lesions
affecting 20% or less of the glomerular area; 2 5 lesions
affecting 21 to 40% of the glomerular area; 3 5 lesions
affecting 41 to 60% of the glomerular area; 4 5 lesions
affecting 61 to 80% of the glomerular area; and 5 5 lesions
exceeding 80% of the glomerular area. A glomerulosclero-
sis index (GSI) was calculated for each rat as the weighted
average of all individual glomerular scores thus obtained,
multiplied by 100. At least 150 glomeruli were examined for
each rat. To assess the extent of interstitial expansion, the
fraction of renal cortex occupied by interstitial tissue
staining positively for collagen was quantitatively evaluated
in Masson-stained sections by a point counting technique
[18] in 25 consecutive microscopic fields, at a final magni-
fication of 4003 under a 100-point ocular grid.
Immunohistochemistry
Optimal working dilutions of the primary antibodies
were previously determined by titration experiments. Neg-
ative control experiments for all antigens were performed
by omitting the incubation with the primary antibody.
To detect T-lymphocytes, 5-mm-thick cryostat renal sec-
tions were fixed in cold acetone and analyzed using a
monoclonal mouse anti-rat CD-3 antibody (Seralab, Ox-
ford, UK) and an indirect streptavidin-biotin alkaline phos-
phatase technique. Sections were preincubated with normal
horse serum (Vector Labs, Burlingame, CA, USA) to
reduce nonspecific staining and then with avidin and biotin
solutions to block nonspecific binding of these compounds.
The incubation with the primary antibody was carried out
at room temperature for 90 minutes. Sections were then
incubated with rat-adsorbed biotinylated anti-mouse IgG
(Vector Labs) for 45 minutes at room temperature, fol-
lowed by incubation with the streptavidin-biotin-alkaline
phosphatase complex (Dako Co, Denmark) for 30 minutes
at room temperature. Sections were incubated with a
freshly prepared substrate, consisting of naphthol AS-MX-
Phosphate (Sigma Chemical Co., St Louis, MO, USA) and
fast red dye (Sigma Chemical Co.), counterstained with
Mayer’s haemalaum (Merck, Darmstadt, Germany) and
covered with Kaiser’s glycerin-gelatin (Merck).
Macrophages and proliferating cells were analyzed in 2
to 3 mm-thick paraffin-embedded sections at 7, 14, 30 and
60 days of ablation. Sections were mounted on glass slides
coated with 2% gelatin, deparaffinized in xylene and rehy-
drated through graded ethanol and in deionized water in
the final step. Sections were then subjected to microwave
irradiation in citrate buffer to enhance antigen retrieval,
and preincubated with 5% normal rabbit serum in Tris
buffered saline (TBS) or in phosphate buffered saline
(PBS) to prevent nonspecific protein binding.
To identify proliferating cells in the kidney tissue, a
monoclonal antibody (Dako Co., Denmark) specific for the
proliferating cell nuclear antigen (PCNA) was employed,
using an avidin-biotinylated horseradish peroxidase (HRP)
method. After blocking endogenous peroxidase activity
with 3% hydrogen peroxide in methanol at room temper-
ature, sections were incubated in a humidified chamber
with the primary antibody overnight at 4°C. After rinsing,
the slides were incubated with biotinylated horse anti-
mouse antiserum (Vector Co.) and then with an avidin-
biotin complex/HRP (Vector Co.). Slides were then devel-
oped with a freshly prepared 3-amino-9-ethylcarbazole
(AEC) chromogen (Sigma Chemical Co.,) in the presence
of 0.03% H2O2. Sections were counterstained with methyl
green (Merck) and covered with Kaiser’s glycerin-gelatin
(Merck).
For specific immunostaining of macrophages, a mono-
clonal mouse anti-rat ED-1 antibody (Serotec, Oxford,
UK) was used. The incubations were carried out overnight
at 4°C in a humidified chamber. After washing, the sections
were incubated with rabbit anti-mouse immunoglobulins
(Dako Co.). To complete the sandwich technique, incuba-
tion with a soluble complex of alkaline phosphatase anti-
alkaline phosphatase (APAAP; Dako Co.) was performed.
The last two steps were repeated to enhance the intensity of
the reaction product. Finally, the slides were developed
with a fast-red dye solution, and counterstained as in the
lymphocyte detection procedure.
The quantitation of PCNA-, ED-1- and CD-3-positive
cells was carried out in a blind fashion under 2003
magnification by two independent investigators and ex-
pressed as cells/0.13 mm2. For each section, 15 to 25
microscopic fields (21 on average), each corresponding to
an area of 0.13 mm2, were examined. The percentage of
Table 1. Renal and systemic functional and hemodynamic parameters 30 days after 5/6 nephrectomy (NX)
Group
Body wt LKW
MAP
mm Hg
GFR RPF
PGC
mm Hg
CA
g/dl
RVR
mm Hg/ml/min
VG
106 mm3g ml/min
Sham 301 6 4 1.43 6 0.08 102 6 2 1.34 6 0.04 3.88 6 0.20 52 6 1 5.8 6 0.1 14.4 6 0.8 1.0 6 0.06
NX 278a 6 3 1.33 6 0.06 132a 6 4 0.77a 6 0.08 2.36a 6 0.28 66a 6 3 5.8 6 0.1 38.2a 6 7.1 1.50a 6 0.06
NX 1 MMF 270a 6 3 1.22a 6 0.03 112ab 6 3 0.83a 6 0.08 3.20 6 0.50 66a 6 2 5.8 6 0.1 25.9 6 4.2 1.41a 6 0.05
Results are expressed as mean 6 1 SE. Abbreviations are: body wt, body weight; LKW, left kidney weight; MAP, mean arterial pressure; GFR,
glomerular filtration rate; RPF, renal plasma flow; PGC, glomerular hydraulic pressure; CA, plasma total protein concentration; RVR, renal vascular
resistance; VG, glomerular volume.
a P , 0.05 vs. Sham
b P , 0.05 vs. NX
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cells located at the glomerulus, tubules and interstitium was
also determined.
Analytical methods
Urinary albumin excretion rate was determined by radial
immunodiffusion. Total plasma protein concentration was
determined by refractometry. Serum creatinine concentra-
tion was assessed by a colorimetric method [19].
Statistics
One-way analysis of variance with pairwise comparisons
according to the Bonferroni method was employed in this
study [20]. P levels of 0.05 or less were significant. Since
GSI and albumin excretion rates were not normally distrib-
uted, log transformations were performed prior to statisti-
cal analysis of these parameters.
RESULTS
We assessed the renal hemodynamics in four untreated
and four MMF-treated rats 30 days after sham operation.
The average values for body weight, left kidney weight
(LKW), mean arterial pressure (MAP), glomerular filtra-
tion rate (GFR), renal plasma flow (RPF), renal vascular
resistance (RVR), PGC, tubular hydraulic pressure (PT),
and efferent arteriolar hydraulic pressure (PE) were nearly
identical to those observed in untreated sham-operated
rats. Likewise, administration of MMF to Sham rats for up
to 60 days was not associated with any difference between
untreated and MMF-treated rats regarding body weight,
LKW, hematocrit (Hct), tail cuff pressure (TCP), urinary
albumin excretion (UalbV), or plasma creatinine concentra-
tion. Finally, careful examination of renal tissue at 60 days
of treatment disclosed no noteworthy glomerular, vascular
or interstitial abnormalities in either untreated or MMF-
treated Sham rats. For these reasons, observations made in
untreated and MMF-treated Sham rats at both 30 and 60 days
after sham-operation were pooled into a single Sham Group.
Renal hemodynamic studies
Renal and systemic functional and hemodynamic param-
eters at 30 days after renal ablation are given in Table 1.
Renal mass reduction was associated with lower body wts in
both NX groups compared with the Sham animals. MMF
treatment promoted no further slowing of body growth.
Renal ablation was associated with elevation of MAP in
Group NX (132 6 4 mm Hg vs. 102 6 2 in Sham, P , 0.05).
Treatment with MMF reduced MAP in Group NX1MMF,
although values remained higher than in sham-operated
rats (112 6 3 mm Hg, P , 0.05 vs. Sham and NX). The
remnant kidneys were slightly and not significantly smaller
than intact kidneys (1.33 6 0.06 g in Group NX vs. 1.43 6
0.08 in Sham, P . 0.05). This indicates the occurrence of
marked hypertrophy of the remnant tissue, since the renal
mass was initially reduced by 83% in these rats. Treatment
with MMF slightly attenuated renal hypertrophy (1.22 6
0.03 g in Group NX1MMF, P , 0.05 vs. Sham and P .
0.05 vs. NX). No differences were observed among groups
when LKW was factored by the respective body weights
(data not shown). By a similar reasoning, remnant
nephrons must have undergone marked hyperfiltration,
since whole kidney GFR fell by only 42% after renal
ablation (0.77 6 0.08 ml/min in Group NX vs. 1.34 6 0.04
in Sham, P , 0.05). The administration of MMF promoted
no further alteration in remnant kidney GFR (0.83 6 0.08
in Group NX1MMF, P . 0.05 vs. NX). Likewise, RPF was
decreased in disproportion to renal mass reduction (2.36 6
0.28 ml/min in Group NX vs. 3.88 6 0.20 in Sham, P ,
0.05), indicating hyperperfusion of remnant glomeruli.
Fig. 1. Light microscopy 60 days after renal ablation. (A) Normal glomeruli and interstitium in a Sham rat. (B) Extensive glomerular sclerotic lesion
in a NX rat 60 days after ablation, consisting of deposition of a PAS-positive material with occlusion of capillary loops and adhesion to Bowman’s
capsule. Enlargement and inflammation of the cortical interstitial area, with expansion of the extracellular matrix, tubular collapse and cell infiltration,
are also observed. (C) Attenuation of glomerular and interstitial injury in a NX rat treated with MMF (PAS stain in 3-mm-thick section, 3200).
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Treatment with MMF promoted a numerical increase in
RPF (3.20 6 0.5 ml/min, P . 0.05 vs. Sham and NX).
Predictably, RVR increased in NX rats (38.2 6 7.1, P ,
0.05 vs. Sham). MMF treatment decreased numerically
RVR in Group NX1MMF (25.9 6 4.2 mm Hg/ml/min in
Group NX1MMF, P . 0.05 vs. Sham and NX). Glomer-
ular hydraulic pressure was markedly elevated in Group
NX (66 6 3 mm Hg vs. 52 6 1 in Sham, P , 0.05). MMF
treatment promoted no change in PGC compared with NX
(66 6 2 mm Hg in Group NX1MMF, P , 0.05 vs. Sham
and P . 0.05 vs. NX). No differences in plasma protein
concentrations were observed among groups. Glomerular
volumes were larger in both NX Groups when compared
with Sham (1.50 6 0.06 in Group NX, P , 0.05 vs. 1.0 6
0.06 in Sham and 1.41 6 0.05 in NX1MMF, P , 0.05 vs.
Sham and P . 0.05 vs. NX).
Sixty-day follow-up studies
Body weights were significantly lower in Group NX
compared to Sham (290 6 8 g vs. 340 6 3 in Sham, P ,
0.05). No further growth limitation occurred as a conse-
quence of MMF treatment (294 6 5 g in Group
NX1MMF). No difference among groups was observed
regarding LKW, whether or not it was factored by the
respective body weight. Tail-cuff pressure was markedly
elevated in NX rats (151 6 6 mm Hg vs. 107 6 2 in Sham,
P , 0.05). Treatment with MMF reduced tail-cuff pressure
in Group NX1MMF, although values remained signifi-
cantly higher than in Sham (126 6 5, P , 0.05 vs. Sham and
NX). Plasma creatinine concentration (PCr) was markedly
elevated in Group NX compared with Sham (1.32 6 0.10
mg/dl vs. 0.51 6 0.03 in Sham, P , 0.05). Treatment with
MMF numerically reduced PCr (1.08 6 0.08 mg/dl in Group
NX1MMF, P . 0.05 vs. NX and P , 0.05 vs. Sham). The
urinary albumin excretion rate was markedly increased in
NX relative to Sham (78 6 8 mg/24 hr vs. 1.4 6 0.2 in
Sham, P , 0.05). MMF treatment promoted no significant
change in albuminuria compared with NX (70 6 14 mg/24
hr in Group NX1MMF, P , 0.05 vs. Sham and P . 0.05 vs.
NX).
Renal histology
Glomerular sclerotic lesions and interstitial expansion
were evident in renal tissue obtained from NX rats 60 days
after ablation (Fig. 1B). Accordingly, the glomerulosclero-
sis index (Fig. 2A) was markedly elevated in Group NX
(68 6 24 vs. 1.0 6 0.1 in Sham, P , 0.05). Treatment with
MMF reduced GSI by 74% (Figs. 1C and 2A), although the
values remained significantly higher in Group NX1MMF
than in Sham (18 6 6, P , 0.05 vs. Sham and NX).
Likewise, the fraction of renal parenchyma occupied by
interstitial tissue (Figs. 1B and 2B) was markedly increased
in NX rats (8.1 6 1.5% in Group NX vs. 0.2 6 0.1 in Sham,
P , 0.05). Treatment with MMF drastically reduced inter-
stitial expansion in Group NX1MMF (Figs. 1C and 2B)
compared with NX (2.7 6 0.5%, P , 0.05 vs. NX and P .
0.05 vs. Sham).
Immunohistochemistry
Figure 3 A through I depict the immunohistochemical
analysis of the renal tissue for the CD-3 and PCNA
antigens at seven days, and for the ED-1 antigen at 60 days,
after ablation. The density of cells expressing the lympho-
cyte-specific CD-3 antigen was very low in Sham (Fig. 3A)
and markedly increased in the interstitium of NX rats (Fig.
3B). MMF markedly reduced CD-3 expression in treated
rats (Fig. 3C). Only rare PCNA-positive cells were seen in
Sham rats (Fig. 3D). By contrast, PCNA was exuberantly
expressed in NX rats (Fig. 3E). MMF treatment largely
attenuated this proliferative response (Fig. 3F). Few ED-
1-positive cells were observed in Sham rats (Fig. 3G). The
expression of the ED-1 antigen was markedly increased in
NX rats (Fig. 3H). MMF treatment limited the number of
ED-1-positive cells in Group NX1MMF (Fig. 3I).
The number of CD-3-positive cells at 7 and 30 days after
ablation is represented in Figure 4. While the expression of
Fig. 2. The glomerulosclerosis index (A) and the percent renal cortical
area occupied by interstitium (B) in the Sham, NX and NX1MMF
Groups 60 days after renal ablation. *P , 0.05 versus Sham. †P , 0.05
versus NX.
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these cells was negligible in Sham, NX rats exhibited a
striking increase in lymphocyte infiltration at both time
points. MMF treatment markedly reduced CD-3 expression
at seven days, and completely normalized the number of
CD-3-positive cells at 30 days.
The time course of the renal PCNA and ED-1 expres-
sions is given in Figure 5 A and B, respectively. In
accordance with previous reports [4, 5], the frequency of
PCNA-positive cells sharply increased in NX rats at seven
days after ablation and thereafter declined gradually, never
returning to baseline (Fig. 5A). Most of these proliferating
cells were located at the tubules, although a considerable
fraction also appeared at the interstitium. MMF treatment
reduced the number of PCNA-positive cells at all time
points (Fig. 5A). The expression of the ED-1 antigen was
also markedly increased at seven days of ablation. At
variance with PCNA, however, ED-1 expression increased
progressively with time, reaching a maximum at the end of
the study. Most of these cells appeared at the interstitial
area (Fig. 5B). MMF treatment reduced ED-1 expression
at seven days and drastically limited the progressive mac-
rophage infiltration observed in untreated rats.
DISCUSSION
As shown previously [21], rats subjected to NX and
examined 30 days after ablation exhibited systemic hyper-
tension and single nephron hyperfiltration and hyperperfu-
sion, in conjunction with glomerular capillary hypertension
and tuft enlargement. Glomerulosclerosis and interstitial
expansion, associated with creatinine retention, systemic
hypertension and marked albuminuria, were observed at 60
days after ablation. Treatment with MMF, an immunosup-
pressor currently used to prevent allograft rejection, signif-
icantly attenuated these structural abnormalities, consistent
with recent preliminary reports that MMF may favorably
impact on human [22] and experimental [23] progressive
nephropathies. MMF treatment also promoted a numerical
decrease in plasma creatinine concentration, although this
failed to achieve statistical significance. It must be noted
that a substantial degree of functional adaptation of the
remaining units is known to accompany progressive
nephron destruction, and that for this reason the GFR may
not decline in proportion to the loss of renal mass [24, 25].
These beneficial effects of MMF on renal structure are
even more notable since the renal alterations attending this
model are not attributed to a primary immunologic disor-
der.
The marked, previously unreported lowering of blood
pressure associated with MMF treatment may have con-
tributed significantly to limit renal injury in NX rats [26],
although it is unclear whether renal protection was a cause
or a consequence of the lowered blood pressure. It must be
noted that the hypertension observed in this study was no
worse than in the spontaneously hypertensive rat (SHR)
[27] or in the Milan hypertensive rat (MHR) [28], which
develop no significant renal structural abnormalities until
advanced age. Amelioration of hypertension alone is insuf-
ficient to prevent progressive renal injury in the ablation
model, unless blood pressure reduction is transmitted to
the glomerular microcirculation [29]. In the present study,
PGC remained elevated in MMF-treated rats despite blood
pressure amelioration, while whole kidney vascular resis-
tance decreased by 32%, suggesting a predominantly affer-
ent vasodilation (most likely autoregulatory, although a
more direct effect of MMF cannot be excluded). Thus, the
beneficial effect of MMF cannot be attributed to preven-
tion of glomerular hemodynamic stress, one of the major
mechanisms thought to initiate progressive renal injury [1,
30]. Attenuation of renal injury was also unrelated to
amelioration of glomerular hypertrophy [3], since glomer-
ular volumes remained high in treated rats, or to primary
amelioration of glomerular barrier function [31], since
MMF treatment did not reduce proteinuria.
Renal injury in NX rats was likely associated with the
several cell abnormalities detected in NX rats. The finding
of an early interstitial infiltration by T-lymphocytes ob-
served in these animals suggests that these cells may have
contributed to the subsequent development of renal injury.
Lymphocytes are quickly recruited in immune-mediated
glomerulonephritis and graft rejection, and may be indis-
pensable for these processes to develop [32–34]. In addi-
tion, since lymphocytes interact with macrophages in a
mutual and complex manner [35, 36], they may govern the
accumulation of these cells in chronic inflammatory pro-
cesses and even in “nonimmunologic” models such as renal
ablation, which likely incorporate several elements of
chronic inflammation [37, 38].
As reported previously [4, 5], NX rats developed an early
surge of renal cell proliferation, which peaked at seven
days, then gradually declined, though never descending to
control levels. Most of this proliferative activity was ob-
served in tubular cells, which might either reflect a hyper-
plastic compensatory response [5] or underlie a possible
Fig. 4. Renal expression of lymphocyte-specific CD-3 antigen at 7 and 30
days after ablation in Sham (), NX (F) and NX1MMF (E).
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Fig. 3. Immunohistochemical demonstration in the renal parenchyma of cells expressing the lymphocyte-specific antigen CD-3 (A through C), PCNA
(D through F) and ED-1 (G through I). (A) CD-3-positive cells are rare in Sham. (B) Numerous CD-3-positive cells are seen in the renal interstitium
of a rat from Group NX seven days after ablation. (C) Only few CD-3-positive interstitial cells in a rat from Group NX1MMF seven days after ablation.
(D) PCNA-positive cells are infrequent in Sham. (E) Intense expression of PCNA, especially in tubules and, to a lesser extent, in the interstitium, in
a rat from Group NX seven days after renal ablation. (F) Much less numerous PCNA-positive cells in a rat from Group NX1MMF seven days after
renal ablation. (G) Macrophage-specific ED-1 positive cells are rarely seen in Sham. (H) ED-1 positive cells are abundant, especially at the interstitium,
60 days after renal ablation. (I) much less frequent ED-1-positive cells in a rat from Group NX1MMF (3400).
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participation of tubular cells in the pathogenesis of inter-
stitial fibrosis [5, 39–41]. A substantial proportion of
PCNA-positive cells located at the interstitium, suggesting
that inflammatory cells also account for the proliferative
activity detected in NX rats. This view is strengthened by
the observation that, in addition to lymphocytes, large
numbers of macrophages accumulated progressively in the
interstitial area. Macrophages are central to cell-mediated
immunity and chronic inflammation and are believed to
participate in the development of renal injury in renal
ablation [4, 5] as well as in other experimental models [4, 5,
42, 43] by interacting with lymphocytes and by releasing a
host of cytokines and growth factors [36, 44].
Treatment of NX rats with MMF attenuated lympho-
cyte infiltration, tubulointerstitial proliferation and the
late accumulation of macrophages in the renal paren-
chyma. Previous observations showed that MMF amelio-
rates immune-mediated processes such as allograft re-
jection [10, 11] and, more recently, experimental lupus
nephritis [45], presumably by limiting lymphocyte prolifer-
ation. In the present study, we demonstrate that this anti-
lymphocytic effect of MMF treatment can also favorably
Fig. 5. Time-dependent renal expression of PCNA (A) and ED-1 (B) in Sham (), NX (F) and NX1MMF (E) in glomeruli (top), tubules (middle)
and interstitium (bottom).
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impact on a “nonimmunologic” process of progressive
renal injury. Lymphocyte inhibition may have interrupted
the vicious cycle originating from the mutual stimulation of
lymphocytes and macrophages, resulting in reduced accu-
mulation of the latter and strongly attenuating glomerulo-
sclerosis and interstitial fibrosis. Additional benefits may
have derived from limitation of tubule cell proliferation
[41]. These observations are consistent with the view that
“immunologic” and “nonimmunologic” mechanisms can
coexist and cooperate in the pathogenesis of chronic ne-
phropathies [7, 8]. We have recently reported that chronic
treatment with a nonsteroidal antiinflammatory drug mark-
edly ameliorates renal injury in the NX model [38]. The
present observations show for the first time that MMF has
similar effects and might be useful in the current effort to
prevent or retard progression of human chronic renal
disease.
In summary, MMF, a specific inhibitor of lymphocyte
proliferation, ameliorates renal injury in the renal ablation
model. The mechanisms underlying this effect do not
include limitation of glomerular hypertension, glomerular
hypertrophy or glomerular barrier dysfunction. Rather,
lymphocyte inhibition, with consequent limitation of pro-
liferative activity and macrophage accumulation, seems to
be key to this protective effect. Further research is war-
ranted to fully elucidate these mechanisms and to ascertain
the possible usefulness of this drug in the treatment of
human disease.
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APPENDIX
Abbreviations used in this article are: AEC, 3-amino-9-ethylcarbazole;
AG, glomerular cross-section area; FF, filtration fraction; GFR, glomeru-
lar filtration rate; GSI, glomerulosclerosis index; GTP, guanosine 59-
triphosphate; Hct, hematocrit; HRP, horseradish peroxidase; LKW, left
kidney weight; MAP, mean arterial pressure; MMF, mycophenolate
mofetil; MPA, mycophenolic acid; NX, 5/6 renal ablation; PBS, phosphate
buffered saline; PCr, plasma creatinine concentration; PCNA, proliferat-
ing cell nuclear antigen; PGC, glomerular hydraulic pressure; RPF, renal
plasma flow; RVR, renal vascular resistance; Sham, sham operated
animals; TBS, Tris buffered saline; UalbV, urinary excretion of albumin.
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